Managing menopausal symptoms after gynecological cancer.
OBJECTIVE
As the length of survival in patients with gynecological malignancies increases due to advances in early diagnosis and therapy, quality of life becomes a major issue for the survivors. These women frequently suffer symptoms following an iatrogenically induced menopause. Many gynecologists advise these patients against hormonal replacement therapy. This review attempts to provide the clinician with information based on current evidence.


RESULTS
The most recent two prospective studies did not find an increase in the recurrence rates in endometrial cancer patients who used hormonal replacement therapy. To date, there are few studies on hormonal replacement therapy in patients with ovarian cancer but the available data suggest that there is no detriment to overall or disease-free survival. There are no data showing an association between poorer outcome and hormonal replacement therapy use in patients with cervical or vulvar cancers.


CONCLUSIONS
There is no evidence showing hormones negatively influence survival after treatment for epithelial ovarian, squamous cervical or vulvar cancer. Their use can be considered in symptomatic patients with endometrial cancer, after weighing the benefits against the risk of recurrence. Gynecologic cancer survivors suffering from menopausal symptoms should be supported by advice about the alternatives to hormonal replacement therapy and by giving them nonbiased information on the present knowledge on the effects of hormonal use in women with a previous cancer. It is reasonable to prescribe hormonal replacement therapy to symptomatic, well informed patients.
Michaelson-Cohen
Rachel
R
Department of Gynecology, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel. rachelmc@szmc.org.il
Beller
Uziel
U
D016889:Endometrial Neoplasms / Q000150:complications; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D005260:Female; D005833:Genital Neoplasms, Female / Q000150:complications*; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D009364:Neoplasm Recurrence, Local / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000150:complications; D018570:Risk Assessment; D012307:Risk Factors